Lipoprotein(a) and cardiovascular disease

This Lancet review is, as of its writing, the authoritative word on lipoprotein(a) — from the Copenhagen group whose population studies built much of the field.

The headline statistics are striking: roughly 1 in 5 people carry an Lp(a) level high enough to raise their risk of both atherosclerotic disease and aortic valve stenosis, and more than 90% of where a person’s level falls is genetic. The review details the texture — variation by ancestry (though risk per unit is similar across groups), a 17% higher level in post-menopausal women than men, and the dual pathology that makes Lp(a) damage both arteries and heart valves. The therapeutic horizon is the exciting part: at least five drugs in development achieving 65–98% Lp(a) reduction, three already in large cardiovascular outcome trials.

The practical takeaway is settled and simple: measure Lp(a) once in higher-risk individuals; since you can’t change the number, use it to drive aggressive control of everything else — and prepare for the targeted therapies now being tested.

We rate the evidence high: a Lancet review from the world’s leading Lp(a) authority, comprehensive across biology, genetics, epidemiology, and the drug pipeline. Its clinical significance is high — it addresses a condition affecting a fifth of the population and frames the management approach just as the field stands on the edge of its first specific treatments.